Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta3-adrenoceptors in urinary bladder.

Osamu Yamaguchi, Christopher R Chapple

    Neurourology and Urodynamics
    |June 30, 2007
    PubMed
    Summary
    This summary is machine-generated.

    Beta-3 adrenoceptors (AR) are key in human bladder smooth muscle relaxation, offering potential for overactive bladder (OAB) treatments. Research focuses on developing selective beta-3 AR agonists to improve OAB therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Are There Potential New Therapeutic Avenues for Treating Idiopathic Nocturia? ICI-RS 2025.

    Neurourology and urodynamics·2025
    Same author

    A critical comparison of polypropylene and polyurethane sling materials after implantation in a suburethral sheep model.

    Biomaterials·2025
    Same author

    What Is Required for AI to Improve the Assessment and Treatment of Patients With Lower Urinary Tract Dysfunction? ICI-RS 2025.

    Neurourology and urodynamics·2025
    Same author

    From Clinical Trials to Routine Practice: Are Urodynamics Still Useful?

    European urology·2025
    Same author

    Do We Need to Re-Focus on Functional Female Urethral Disorders in Lower Urinary Tract Dysfunction? ICI-RS 2024.

    Neurourology and urodynamics·2024
    Same author

    Development of a Clinically Relevant Preclinical Animal Model to Mimic Suburethral Implantation of Support Materials for Stress Urinary Incontinence.

    Neurourology and urodynamics·2024
    Same journal

    Letter to the Editor: Effect of Acupressure on Anxiety, Embarrassment, and Procedural Fear in Patients Undergoing Urodynamic Testing: Randomized Controlled Study.

    Neurourology and urodynamics·2026
    Same journal

    Re: "Transurethral Resection of the Prostate in Patients With Neurogenic Lower Urinary Tract Dysfunction".

    Neurourology and urodynamics·2026
    Same journal

    Letter to the Editor in Response to "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

    Neurourology and urodynamics·2026
    Same journal

    Tips and Tricks for Preventing and Managing Urinary Stoma Complications in the Neurogenic Bladder Population.

    Neurourology and urodynamics·2026
    Same journal

    Reply to the Letter to the Editor Regarding "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

    Neurourology and urodynamics·2026
    Same journal

    Letter to the Editor on "A Novel Template for Intravesical Botulinum Toxin Injection in Patients With Idiopathic Overactive Bladder: A Cohort Study".

    Neurourology and urodynamics·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Urology

    Background:

    • Beta-adrenoceptors (AR) include beta(1), beta(2), and beta(3) subtypes.
    • Beta-3 AR is predominantly expressed in human bladder smooth muscle (97% of beta-AR mRNA).
    • Beta-3 AR mRNA is also found in the human bladder urothelium.

    Discussion:

    • Species-dependent distribution of beta-AR subtypes influences detrusor muscle relaxation.
    • cAMP-dependent pathways are not the sole mechanism for beta-AR-mediated smooth muscle relaxation.
    • Calcium-activated K+ channels (BKca channels) play a role in smooth muscle relaxation, particularly against KCl-induced tone.

    Key Insights:

    • Beta-3 AR agonists show promise for treating overactive bladder (OAB) by increasing bladder capacity with minimal side effects in rat models.
    • Pharmacological differences exist between rat and human beta-3 ARs.

    Related Experiment Videos

  • The tryptophan 64 arginine polymorphism in the beta-3 AR gene is associated with idiopathic OAB.

    • Outlook:

    • Developing highly selective human beta-3 AR agonists is crucial for effective OAB therapy.
    • Screening techniques using transfected cell lines can identify selective compounds.
    • Targeting beta-3 AR offers a potential therapeutic strategy for managing OAB symptoms.